Vaxcyte, Inc. $PCVX Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 5.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,110 shares of the company’s stock after acquiring an additional 772 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Vaxcyte were worth $459,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Rhumbline Advisers raised its position in shares of Vaxcyte by 5.5% during the 1st quarter. Rhumbline Advisers now owns 181,230 shares of the company’s stock worth $6,843,000 after acquiring an additional 9,416 shares in the last quarter. Harbor Capital Advisors Inc. increased its position in Vaxcyte by 32.8% during the second quarter. Harbor Capital Advisors Inc. now owns 102,362 shares of the company’s stock worth $3,328,000 after buying an additional 25,303 shares during the period. Intech Investment Management LLC increased its position in Vaxcyte by 44.3% during the first quarter. Intech Investment Management LLC now owns 89,212 shares of the company’s stock worth $3,369,000 after buying an additional 27,384 shares during the period. Strs Ohio acquired a new position in Vaxcyte during the first quarter worth approximately $627,000. Finally, Polar Asset Management Partners Inc. acquired a new position in Vaxcyte during the first quarter worth approximately $378,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Trading Up 4.1%

Shares of PCVX stock opened at $43.70 on Friday. The business’s 50 day moving average is $33.48 and its two-hundred day moving average is $34.15. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $118.62. The company has a market capitalization of $5.67 billion, a P/E ratio of -10.63 and a beta of 1.12.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter in the prior year, the firm posted ($1.10) earnings per share. As a group, equities analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the company. The Goldman Sachs Group assumed coverage on Vaxcyte in a research report on Friday, September 12th. They set a “neutral” rating and a $38.00 price target on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vaxcyte in a research report on Saturday, September 27th. Finally, Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $106.25.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.